比音勒芬(002832.SZ):謝挺已通過集中競價累計減持1709.1061萬股
格隆匯 5 月 7日丨比音勒芬(002832.SZ)公佈,公司近日收到股東謝挺及其一致行動人的通知,2020年2月26日至2021年5月6日期間,信息披露義務人謝挺因自身資金需求減持上市公司股份,以及“比音轉債”於2020年12月21日進入轉股期,股本增加引起持股比例被動稀釋。截至2021年5月6日,信息披露義務人謝秉政、馮玲玲、謝挺所持股份比例累計減少5.01%。
其中,謝挺已於2020年2月26日-2021年5月6日通過集中競價減持1709.1061萬股,減持比例3.23%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.